Latest Capital Raising News

TerraCom Limited has announced a partially underwritten renounceable entitlement offer aiming to raise approximately A$60 million to bolster its financial position amid ongoing coal price pressures. Key directors have committed to participate, while substantial shareholder Orbit Marketing stands ready to underwrite a significant portion of any shortfall.

TerraCom Limited confirms stable mining operations at Blair Athol despite logistical hurdles, while launching a A$60 million capital raise to bolster liquidity amid shipment timing challenges.

ActivEX Limited has completed a $100,000 share placement with Business Victor Investments Limited, aiming to accelerate its exploration activities and strengthen working capital.

Corella Resources has completed the first tranche of a $1 million share placement, issuing over 142 million shares at $0.0035 each. The second tranche and attached options await shareholder approval in early 2026.

InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.

Pure Resources has completed a $1.7 million placement to fund its Garnet Hills Garnet and Graphite Project, with options to be issued pending shareholder approval.

DevEx Resources has successfully raised nearly $7 million through an oversubscribed Share Purchase Plan, significantly exceeding its initial $3 million target to fund expanded uranium exploration in Australia’s Northern Territory.

Wingara AG Limited has arranged a $250,000 unsecured loan facility from NAOS Asset Management entities, featuring a convertible note option that could reshape its capital structure.

American Tungsten & Antimony Ltd plans to unlock value by spinning out its Drummond Basin and NSW gold exploration assets into a new ASX-listed company, King Metals Limited, aiming to raise up to $6 million in an IPO.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.